Prior studies have reported significant downregulation of FOXA1 in NPC tissues and cell lines, correlating with advanced clinical stages and poor differentiation, which suggests its potential as a tumor suppressor [18–20]. The gene discussed is FOXA1; the disease is nasopharyngeal carcinoma.